Products for Research Use Only
RegisterLogin

Silmitasertib

CAT: 0804-HY-50855-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50855-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
CAS Number
1009820-21-6
Product Name Alternative
CX-4945
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Casein Kinase
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CX-4945.html
Concentration
10mM
Purity
99.94
Solubility
0.1 M NaOH : 33.33 mg/mL (ultrasonic; adjust pH to 9 with NaOH) |DMSO : ≥ 35 mg/mL
Smiles
O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O
Molecular Formula
C19H12ClN3O2
Molecular Weight
349.77
Precautions
H302, H315, H319, H335
References & Citations
[1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70 (24) :10288-98.|[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7 (2) :1323-40.|[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CK2
Citation 01
Autophagy. 2025 Jan;21 (1) :178-190.|Biochem Biophys Res Commun. 2020 Oct 20;531 (3) :409-415.|Biochem Pharmacol. 2025 Apr 8:116933.|Biomed Pharmacother. 2024 Jul 29:178:117191.|bioRxiv. 2023 Oct 23:2023.10.20.563266.|bioRxiv. 2024 Jul 25:2024.07.25.605073.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2025 April 09.|bioRxiv. 2025 February 07.|bioRxiv. 2025 Sep 26:2025.09.24.677357.|Cancer Biol Ther. 2025 Dec;26 (1) :2457777.|Cancers (Basel) . 2021 Mar 5;13 (5) :1127.|Cell Death Dis. 2024 Mar 16;15 (3) :223.|Cell Death Discov. 2024 Apr 22;10 (1) :185.|Cell Mol Biol Lett. 2023 Oct 24;28 (1) :85.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2023 Apr 3;42 (4) :112339.|Cell Stem Cell. 2023 Apr 6;30 (4) :450-459.e9.|Cells. 2021 Jan 18;10 (1) :181.|Drug Res (Stuttg) . 2024 Apr;74 (4) :187-190.|Electronic Theses and Dissertations. 2023 Jul.|EMBO Mol Med. 2020 Aug 7;12 (8) :e11987.|Heliyon. 2024 Aug 18;10 (16) :e36205.|Immunol Cell Biol. 2025 Jan;103 (1) :73-92.|Int J Biol Macromol. 2024 Dec 2:138305.|Int J Mol Sci. 2020 Mar 3;21 (5) :1718.|Invest Ophthalmol Vis Sci. 2022 Dec 1;63 (13) :14.|iScience. 2025 Jan 7;28 (2) :111765.|J Biol Chem. 2024 Nov;300 (11) :107848.|J Immunol. 2023 May 1;210 (9) :1396-1407.|J Med Chem. 2023 Mar 23;66 (6) :4009-4024.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|Nat Cell Biol. 2021 Mar;23 (3) :257-267.|Nat Commun. 2023 Feb 9;14 (1) :731.|Nat Commun. 2024 Oct 16;15 (1) :8912.|Nat Plants. 2025 Aug;11 (8) :1572-1590.|Oncogene. 2017 Aug 24;36 (34) :4943-4950.|Oncogene. 2022 Jan;41 (4) :571-585.|Oncol Rep. 2017 Feb;37 (2) :1141-1147. |Patent. US20180263995A1.|Patent. US20250228978A1.|PLoS Pathog. 2025 Sep 10;21 (9) :e1013464.|Research Square Preprint. 2023 May 26.|Research Square Preprint. 2023 Oct 27.|Sci Rep. 2025 Jul 1;15 (1) :20922.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Signal Transduct Target Ther. 2023 May 10;8 (1) :183.|University of California. 2023 Feb.|University of Concepcion. 2023.|University of Washington. 2025.|Cancer Cell Int. 2024 Dec 26;24 (1) :432.|Int J Mol Sci. 2021 Jan 15;22 (2) :819.|Metabolism. 2024 Nov 7:162:156060.|Oncotarget. 2016 Aug 16;7 (33) :53191-53203.

Alternative Products

CatalogName
abx283579-01Silmitasertib
200843CX4945 (Silmitasertib)
413395Silmitasertib sodium
A8330-1000CX-4945 (Silmitasertib)
S2248-50mgSilmitasertib (CX-4945)
TBI4809-5MGSilmitasertib, CK2 inhibitor
MBS5754751Silmitasertib sodium salt

Popular Products